Skip to main content
. 2021 Nov 13;13(22):5681. doi: 10.3390/cancers13225681

Figure 5.

Figure 5

Targeting the FGFR axis. Aberrant FGFR signalling can contribute to cancer progression and therefore targeting FP-1039. can also block the FGF–FGFR interaction and therefore prohibit FGFR activation. In addition, ligand binding inhibitors that act as antagonists (e.g., PI-88 and sm27) can prevent FGFR activation. Monoclonal antibodies targeting specific FGFR isoforms (e.g., MFGR1877s by Genentech) can also have anti-tumour activity. Created with BioRender.com (accessed on 12 November 2021).